Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Captisol is produced under cGMP controls at two validated sites in Loures, Portugal and Cork, Ireland. Ligand uses a patented all aqueous process to manufacture Captisol. This process results in ultra-low endotoxin, ultra-low bioburden, and low chloride product.
Each lot must meet strict analytical specifications before released. Ligand has 20+ year history of manufacturing reproducible, quality batches of Captisol. While most excipients adhere to the minimum standards of USP and IPEC, Captisol exceeds those guidelines. Click here for example Certificate of Analyses.
When maintained at recommended storage conditions (ambient temperature, protected from moisture), Captisol is stable for at least seven years.
Captisol is available at 100g, 1kg, 5kg, 20kg and metric ton quantities. Contact the Captisol Team to place an order or request a free sample.